T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use
about
Viral entry through CXCR4 is a pathogenic factor and therapeutic target in human immunodeficiency virus type 1 diseaseCCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremiaFunctional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusionEstablishment of a novel CCR5 and CXCR4 expressing CD4+ cell line which is highly sensitive to HIV and suitable for high-throughput evaluation of CCR5 and CXCR4 antagonistsA small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activityVariable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogsHIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 useT134, a small-molecule CXCR4 inhibitor, has no cross-drug resistance with AMD3100, a CXCR4 antagonist with a different structure.Will multiple coreceptors need to be targeted by inhibitors of human immunodeficiency virus type 1 entry?Involvement of both the V2 and V3 regions of the CCR5-tropic human immunodeficiency virus type 1 envelope in reduced sensitivity to macrophage inflammatory protein 1alpha.Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells.Varied sensitivity to therapy of HIV-1 strains in CD4+ lymphocyte sub-populations upon ART initiation.CXCR4 utilization is sufficient to trigger CD4+ T cell depletion in HIV-1-infected human lymphoid tissue.A duodenally absorbable CXC chemokine receptor 4 antagonist, KRH-1636, exhibits a potent and selective anti-HIV-1 activityNucleic acid-based immune system: the antiviral potential of mammalian RNA silencing.Susceptibility of HIV type 2 primary isolates to CCR5 and CXCR4 monoclonal antibodies, ligands, and small molecule inhibitorsThe entry of entry inhibitors: a fusion of science and medicine.Replication-competent variants of human immunodeficiency virus type 2 lacking the V3 loop exhibit resistance to chemokine receptor antagonists.Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.Molecular and phylogenetic analysis of HIV-1 variants circulating in ItalyHuman Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.Inhibition of human immunodeficiency virus replication by a dual CCR5/CXCR4 antagonist.Replacement of the V3 domain in the surface subunit of the feline immunodeficiency virus envelope glycoprotein with the equivalent region of a T cell-tropic human immunodeficiency virus type 1 results in a chimeric surface protein that efficiently bMutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.Evidence for common structural determinants of human immunodeficiency virus type 1 coreceptor activity provided through functional analysis of CCR5/CXCR4 chimeric coreceptorsHuman immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonistsAllosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.
P2860
Q24524292-1AADFA46-3F73-45D5-A251-E10446359791Q24557545-35C49D30-8305-45B9-B23B-B43A603E8F83Q24678540-263E6E67-DE0C-4890-A7EF-CCCF3374CED6Q24802476-1AEB3B86-4500-4DA5-92C8-811D6D6320FBQ28343321-260C8F40-D20D-47B1-873F-8A18CBCE4664Q28344169-37E078C1-82A0-45DF-B623-CC576D4C87EAQ28344746-839A3CA4-CF73-4974-9422-9CA05EBF576DQ28369495-753CB0AC-E0F6-49A6-B890-87D02EE8651BQ33645423-83DE38B5-C685-4729-9639-669EFA87CC19Q33797534-86D5322A-68BE-44EB-AA86-B19F39ECB2FCQ33808728-4365F5B6-EB8D-46DA-8601-0169A5FA523AQ34418967-6123ADC4-0D6C-430E-84D2-3E0DE311D1E9Q34838416-5754B1D6-B94B-43DA-8148-9ADB0A9D1723Q34955359-B8CD1DBE-C2E9-43FF-A253-219C1E9E3525Q35153871-1E810CF8-4063-4CFC-86DD-3E22EFD6B885Q35904711-7AA10EF4-4A3A-41B8-9563-3182E3FA40A3Q35976966-692BCB10-1E94-43AA-B766-50A41C10779DQ36098903-2B046E3A-668B-4003-8CC7-F68CCE0B0DE3Q36509765-D8D5E74D-10BD-4E07-97A6-02A3A878A76EQ36981930-F717041D-9D47-451F-AE94-0FB1F5A91A28Q37102101-287ECF3A-7E78-482C-A748-49AFA57B8202Q37568901-D77929B4-BC14-4D5B-89F4-E4EC496811F2Q37596456-5F3F65D8-98CD-438E-9DFF-233590A8E696Q37610630-62D0B0FB-86E5-4086-8326-9F412526A9CFQ37742855-31727CE7-A0F4-4B70-A508-B545751DF607Q38076139-C1E183E1-BD55-4D7F-B303-2832B0A3E094Q39582046-1F7A0E09-6C0B-4004-8A5F-FAEC2AF24785Q39605336-CE32A9F9-739C-4CCC-BFDF-D164F632B06CQ39830543-A6897FC3-57F9-4476-97A3-15B8AAACF27DQ40584611-26DA3F49-6C6F-4E65-B21C-BEC7D8269E40Q43161389-3818FA61-8872-4BAD-83B0-D9C8E31B180D
P2860
T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@ast
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@en
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@nl
type
label
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@ast
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@en
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@nl
prefLabel
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@ast
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@en
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@nl
P2093
P2860
P1433
P1476
T-cell-line-tropic human immun ...... how a switch in coreceptor use
@en
P2093
P2860
P304
P407
P577
1998-05-01T00:00:00Z